Building better antibodies in pursuit of a broad-spectrum vaccine with Jacob Glanville

from Life Science and Biotech CEO stories · host Tim Dougherty

In this podcast we’re pleased to welcome Jacob Glanville, the CEO of Centivax. He is working on a single, broad-spectrum vaccine, initially for the flu.

Episode metadata supplied by the publisher feed · Published Oct 19, 2022

Embed this episode

Attribution link and audio player

NOW PLAYING

Building better antibodies in pursuit of a broad-spectrum vaccine with Jacob Glanville

0:00 1:15:33

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Life Science and Biotech CEO stories?

This episode is 1 hour and 15 minutes long.

When was this Life Science and Biotech CEO stories episode published?

This episode was published on October 19, 2022.

Can I download this Life Science and Biotech CEO stories episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!